Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today ...

While in the mid-2010s the country’s nominal gross domestic product stood at approximately USD 60-65 billion, it has now ...

Retrieval-augmented generation breaks at scale because organizations treat it like an LLM feature rather than a platform ...

Rocket Pharmaceuticals is a Buy, with strong catalysts, undervalued programs, and significant upside. Click here to read my ...

Precision BioSciences offers high-risk, high-reward potential, trading below cash with key HBV and DMD data catalysts ...

A research team affiliated with UNIST has made a advancement in controlling spin-based signals within a new magnetic material ...

The company’s AI-builder approach with in-house AI innovation and bolt-on acquisitions will be key for its growth in the ...

Recently, micro/nanosatellites have become a significant trend in space with the rapid development of space technology, ...

In 2026, banks face converging pressure from AI, fraud, and data demands. Why hesitation is a competitive risk—and what ...

Data collected under the Death in Custody Reporting Act has some serious problems. Here’s how we fixed some of them.

Medera Inc. ('Medera'), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing ...

The Turkish program validated smart-fleet algorithms with autonomous formation flight and CAP patrol without permanent ...